Abstract

Acute myeloid leukemia is the most common acute leukemia in adults, the barrier of refractory and drug resistance has yet to be conquered in the clinical. Abnormal gene expression and epigenetic changes play an important role in pathogenesis and treatment. A super-enhancer is an epigenetic modifier that promotes pro-tumor genes and drug resistance by activating oncogene transcription. Multi-omics integrative analysis identifies the super-enhancer-associated gene CAPG and its high expression level was correlated with poor prognosis in AML. CAPG is a cytoskeleton protein but has an unclear function in AML. Here we show the molecular function of CAPG in regulating NF-κB signaling pathway by proteomic and epigenomic analysis. Knockdown of Capg in the AML murine model resulted in exhausted AML cells and prolonged survival of AML mice. In conclusion, SEs-associated gene CAPG can contributes to AML progression through NF-κB.

Super-enhancers associated gene CAPG (Capping actin protein, gelsolin-like) regulates Nf-κB signaling in acute myeloid leukemia in a MLL-AF9 mouse model.

Details

Title
Super-enhancer-associated gene CAPG promotes AML progression
Author
Ma, Qian 1 ; Zhao, Minyi 2 ; Long, Bing 3 ; Li, Haixia 1   VIAFID ORCID Logo 

 Peking University First Hospital, Department of Clinical Laboratory, Beijing, China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621) 
 The Seventh Affiliated Hospital, Sun Yat-sen University, Department of Hematology, Shenzhen, China (GRID:grid.511083.e) (ISNI:0000 0004 7671 2506) 
 The Third Affiliated Hospital, Sun Yat-sen University, Department of Hematology, Guangzhou, China (GRID:grid.412558.f) (ISNI:0000 0004 1762 1794) 
Pages
622
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2825561043
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.